Ambev stock reports 6 percent revenue growth in Q2 2026

Published on 09/29/2026 at 19:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ambev stock delivered 6.00 percent organic revenue growth in Q2 2026, while normalized EBITDA rose 8.90 percent. Normalized EPS climbed 24.20 percent to BRL 0.22.

Ambev, BRABEVACNOR1, Illustration mit AI erstellt.

Ambev stock (ISIN BRABEVACNOR1) delivered 6.00 percent organic revenue growth in Q2 2026, with normalized EBITDA rising 8.90 percent to BRL 6.38 billion. The results sharpen the contrast between modest top-line expansion and faster profit growth.

Profit growth outpaces revenue

According to ScanX on September 18, 2026, normalized EPS increased 24.20 percent year over year to BRL 0.22 in Q2FY26. Normalized EBITDA margin expanded 80 basis points to 31.60 percent, showing that profitability grew faster than revenue during the quarter.

Ambev reported Q2 net revenue of BRL 20.15 billion, while GAAP EPS increased 25.40 percent to BRL 0.22, according to the same Q2FY26 results coverage. Operating cash flow reached BRL 7.90 billion in the first half of 2026, up more than 80.00 percent year over year, giving the company room for shareholder distributions and operating investment.

Beer and digital channels lead

Brazil beer volume grew 5.00 percent in Q2FY26, while premium beer volume expanded 20.00 percent, according to ScanX. BEES marketplace gross merchandise value grew 60.00 percent, and marketplace gross margin reached 22.00 percent, making digital distribution a measurable contributor to the operating picture.

For investors, the key comparison is profit quality rather than revenue alone: normalized EPS growth of 24.20 percent was four times the 6.00 percent organic revenue increase. Brazil non-alcoholic beverage volume declined 4.40 percent, creating a counterweight to the stronger beer and premium mix performance.

Analysts remain cautious

MarketBeat reported on September 14, 2026, that six analysts assigned Ambev a Reduce consensus, with five Hold ratings and one Sell rating. The average 12-month price target was USD 3.08, while UBS had set a USD 2.85 target on August 11, 2026.

Ambev's investor-relations page lists the 2Q26 earnings release and results conference call in its Results Center. The next earnings date is October 29, 2026, according to Gekko, giving the market a defined checkpoint for the sustainability of the margin expansion.

Ambev market snapshot

Ambev's NYSE ADR was quoted at USD 2.85 on September 29, 2026 at 1:32 p.m. EDT. The 52-week range was USD 2.10 to USD 3.45, and market capitalization was USD 44.1 billion on the same date.